Early Experience of Aflibercept 8mg (EYLEA® 8mg) in Routine Clinical Practice

Sponsored Supplement: Early Experience of Aflibercept 8mg (EYLEA® 8mg) in Routine Clinical Practice

One-to-one interviews with three leading retina specialists from Switzerland, United Kingdom and United States on their early experience of aflibercept 8mg (EYLEA® 8mg) in clinical practice, capturing contemporary insights on treatment strategies and real-world outcomes in patients with neovascular age-related macular degeneration and diabetic macular edema.